CompletedPhase 3NCT03600376
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
Studying Exercise-induced malignant hyperthermia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eagle Pharmaceuticals, Inc.
- Principal Investigator
- Adrian HepnerEagle Pharmaceuticals, Inc.
- Intervention
- Ryanodex and Standard of Care(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2018 – 2019
Study locations (4)
- King Faisal Hospital, Mecca, Saudi Arabia
- Mina al Jisr Hospital, Miná, Saudi Arabia
- Mina Al-Shari Al-Jadeed Hospital, Miná, Saudi Arabia
- Mina Al-Wadi Hospital, Miná, Saudi Arabia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03600376 on ClinicalTrials.gov